Stock Market Reviews

PGEN (Precigen, Inc.) News

Get the latest news, insights, and market updates on PGEN (Precigen, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Precigen’s (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism
  Precigen Inc. (NASDAQ:PGEN) is one of the best multibagger stocks to invest in right now. Among the company’s proprietary therapeutic platforms, its UltraCAR-T platform offers a differentiated approach to CAR-T treatment, aiming for faster manufacturing and potentially improved safety profiles. The company has multiple candidates progressing through clinical trials, which are being used to build a […]
  Sep 11, 2025 - $PGEN
• EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS
  EVERSANA, a leading provider of global commercialization services to the life sciences industry, has been named by Precigen, Inc. for commercialization of PAPZIMEOS™ (zopapogene imadenovec-drba), approved by the U.S. Food and Drug Administration on August 14, 2025.
  Sep 11, 2025 - $PGEN
• These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
  Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July.
  Sep 7, 2025 - $PGEN
• Precigen Announces Up to $125 Million Non-Dilutive Financing
  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced that it has entered into a credit facility agreement with investment funds managed by Pharmakon Advisors, LP.
  Sep 3, 2025 - $PGEN
• Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN)
  Precigen, Inc. (NASDAQ:PGEN) is one of the must-buy penny stocks to invest in. On August 19, Cantor Fitzgerald reaffirmed its “Overweight” rating on Precigen stock. The firm expressed growing confidence in Precigen’s upcoming launch of Papzimeos, the company’s newly approved product, following recent discussions with the company. Papzimeos received full FDA approval as the first […]
  Sep 2, 2025 - $PGEN
• INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug
  Inovio stock surges 21% after the FDA gives green light to begin a rolling BLA for its RRP drug INO-3107, with plans to seek priority review.
  Aug 28, 2025 - $PGEN